Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 Shares

Key Points

• Ying Du, CEO of Zai Lab Limited, sold 50,000 shares at an average price of $34.64, totaling $1.73 million, resulting in an 8.52% decrease in his ownership of the stock.
• Zai Lab reported negative earnings with an EPS of ($0.37) for the last quarter, meeting analysts' expectations but falling short of revenue forecasts.
• Wall Street analysts have mixed ratings for Zai Lab, with two analysts rating it as a hold and five as a buy, reflecting uncertainty about the stock's future performance.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 50,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $34.64, for a total transaction of $1,732,000.00. Following the completion of the transaction, the chief executive officer directly owned 536,962 shares of the company's stock, valued at $18,600,363.68. The trade was a 8.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ying Du also recently made the following trade(s):

• On Friday, August 8th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.74, for a total value of $1,737,000.00.
• On Wednesday, July 2nd, Ying Du sold 7,072 shares of Zai Lab stock. The shares were sold at an average price of $35.23, for a total value of $249,146.56.
• On Monday, June 30th, Ying Du sold 6,918 shares of Zai Lab stock. The stock was sold at an average price of $35.52, for a total transaction of $245,727.36.
• On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total transaction of $855,160.97.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The shares were sold at an average price of $28.09, for a total transaction of $1,303,067.01.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB traded down $0.35 during midday trading on Tuesday, reaching $34.31. 394,193 shares of the company's stock were exchanged, compared to its average volume of 995,749. The firm's 50 day simple moving average is $36.70 and its two-hundred day simple moving average is $33.36. The stock has a market cap of $3.81 billion, a price-to-earnings ratio of -16.82 and a beta of 1.03. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $16.01 and a fifty-two week high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, meeting analysts' consensus estimates of ($0.37). Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. The company had revenue of $109.98 million during the quarter, compared to analysts' expectations of $125.66 million. Equities research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ZLAB has been the topic of a number of research analyst reports. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an "outperform" rating in a research note on Monday, June 30th. Citigroup reissued a "buy" rating and issued a $69.00 price objective (up from $66.00) on shares of Zai Lab in a research note on Monday. Finally, Wall Street Zen downgraded Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.22.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC boosted its holdings in Zai Lab by 749.1% during the 4th quarter. FMR LLC now owns 5,475,505 shares of the company's stock valued at $143,403,000 after acquiring an additional 4,830,646 shares during the period. Principal Financial Group Inc. boosted its holdings in Zai Lab by 63.6% during the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after acquiring an additional 1,121,856 shares during the period. RTW Investments LP purchased a new position in shares of Zai Lab in the 4th quarter valued at about $65,714,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Zai Lab by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company's stock valued at $61,653,000 after buying an additional 548,378 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after buying an additional 2,127,598 shares during the period. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.